Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

The conditional survival analysis of relapsed DLBCL after autologous transplant: a subgroup analysis of LY.12 and CORAL.

Autor: Assouline S; Lady Davis Institute, Jewish General Hospital, McGill University, Montreal, QC, Canada., Li S; Lady Davis Institute, Jewish General Hospital, McGill University, Montreal, QC, Canada., Gisselbrecht C; Hospital Saint Louis, Paris, France., Fogarty P; Lysarc, Hospital Lyon Sud, Pierre-Bénite, France., Hay A; Canadian Cancer Trials Group, Queens University, Kingston, ON, Canada., van den Neste E; Cliniques Universitaires UCL Saint-Luc, Brussels, Belgium., Shepherd LE; Canadian Cancer Trials Group, Queens University, Kingston, ON, Canada., Schmitz N; University Hospital Münster, Münster, Germany., Baetz T; Kingston General Hospital, Kingston, ON, Canada., Keating A; Princess Margaret Hospital, Toronto, ON, Canada., Robinson S; Queen Elizabeth II Health Sciences Centre, Halifax, NS, Canada., Seftel M; CancerCare Manitoba, Winnipeg, MB, Canada., Stelitano C; Azienda Ospedaliera Bianchi Melacrino Morelli, Reggio Calabria, Italy; and., Djurfeldt MS; Cliniques Universitaires UCL Saint-Luc, Brussels, Belgium., Meyer R; Juravinski Cancer Center, Hamilton, ON, Canada., Chen BE; Cliniques Universitaires UCL Saint-Luc, Brussels, Belgium., Crump M; Princess Margaret Hospital, Toronto, ON, Canada.

Publikováno v: Blood advances [Blood Adv] 2020 May 12; Vol. 4 (9), pp. 2011-2017.

Effect of the addition of rituximab to salvage chemotherapy prior to autologous stem cell transplant in aggressive CD20+ lymphoma: a cohort comparison from the NCIC Clinical Trials Group Study LY.12^.

Autor: Baetz T; a Department of Oncology, Cancer Centre of Southeastern Ontario , Queen's University , Kingston , ON , Canada., Chen BE; b Canadian Cancer Trials Group , Cancer Research Institute, Queen's University , Kingston , ON , Canada., Couban S; c Queen Elizabeth II Heath Sciences Centre , Halifax , NS , Canada., Tom Kouroukis C; d Department of Oncology , Juravinski Hospital and Cancer Centre , Hamilton , ON , Canada., Buckstein R; e Department of Hematology/Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre , University of Toronto , Toronto , ON , Canada., Kuruvilla J; f Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre , University of Toronto , Toronto , ON , Canada., Howson-Jan K; g London Health Sciences Centre , London , ON , Canada., Szwajcer D; h Department of Medicine , University of Manitoba , Winnipeg , MB , Canada., Federico M; i Cattedra Di Oncologia Medica , Università Di Modena E Reggio Emilia , Modena , Italy., Meyer RM; d Department of Oncology , Juravinski Hospital and Cancer Centre , Hamilton , ON , Canada., Djurfeldt MS; b Canadian Cancer Trials Group , Cancer Research Institute, Queen's University , Kingston , ON , Canada., Hay AE; b Canadian Cancer Trials Group , Cancer Research Institute, Queen's University , Kingston , ON , Canada., Shepherd L; b Canadian Cancer Trials Group , Cancer Research Institute, Queen's University , Kingston , ON , Canada., Crump M; f Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre , University of Toronto , Toronto , ON , Canada.

Publikováno v: Leukemia & lymphoma [Leuk Lymphoma] 2017 Jan; Vol. 58 (1), pp. 64-69. Date of Electronic Publication: 2016 Jun 07.

Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12.

Autor: Crump M; Michael Crump, John Kuruvilla, and Vishal Kukreti, Princess Margaret Cancer Centre; Rena Buckstein and Kevin R. Imrie, Odette Cancer Centre and Sunnybrook Health Sciences Centre, Toronto; C. Tom Kouroukis, Jonathan Sussman, and Ralph M. Meyer, Margaret and Charles Juravinski Cancer Centre, Hamilton; Kang Howson-Jan, London Health Sciences Centre, London; Tara Baetz, Cancer Centre of Southeastern Ontario at Kingston General Hospital; Annette E. Hay, Marina S. Djurfeldt, Ralph M. Meyer, Bingshu E. Chen, and Lois E. Shepherd, NCIC Clinical Trials Group, Kingston; Leonard Kaizer, Credit Valley Hospital, Mississauga, Ontario; Stephen Couban and David A. MacDonald, Queen Elizabeth II Health Sciences Centre and Dalhousie University, Halifax, Nova Scotia; Morel Rubinger, Cancercare Manitoba, Winnipeg, Manitoba; Michael Voralia, Saskatoon Cancer Centre, Saskatoon, Saskatchewan; Harold J. Olney, Centre Hospitalier de l'Université de Montréal-Hopital Notre Dame, Montreal, Quebec; A. Robert Turner, Cross Cancer Institute, Edmonton, Alberta, Canada; Massimo Federico, University of Modena and Reggio Emilia, Modena; Nicola Di Renzo, Ospedale Vito Fazzi, Leece, Italy. michael.crump@uhn.on.ca., Kuruvilla J; Michael Crump, John Kuruvilla, and Vishal Kukreti, Princess Margaret Cancer Centre; Rena Buckstein and Kevin R. Imrie, Odette Cancer Centre and Sunnybrook Health Sciences Centre, Toronto; C. Tom Kouroukis, Jonathan Sussman, and Ralph M. Meyer, Margaret and Charles Juravinski Cancer Centre, Hamilton; Kang Howson-Jan, London Health Sciences Centre, London; Tara Baetz, Cancer Centre of Southeastern Ontario at Kingston General Hospital; Annette E. Hay, Marina S. Djurfeldt, Ralph M. Meyer, Bingshu E. Chen, and Lois E. Shepherd, NCIC Clinical Trials Group, Kingston; Leonard Kaizer, Credit Valley Hospital, Mississauga, Ontario; Stephen Couban and David A. MacDonald, Queen Elizabeth II Health Sciences Centre and Dalhousie University, Halifax, Nova Scotia; Morel Rubinger, Cancercare Manitoba, Winnipeg, Manitoba; Michael Voralia, Saskatoon Cancer Centre, Saskatoon, Saskatchewan; Harold J. Olney, Centre Hospitalier de l'Université de Montréal-Hopital Notre Dame, Montreal, Quebec; A. Robert Turner, Cross Cancer Institute, Edmonton, Alberta, Canada; Massimo Federico, University of Modena and Reggio Emilia, Modena; Nicola Di Renzo, Ospedale Vito Fazzi, Leece, Italy., Couban S; Michael Crump, John Kuruvilla, and Vishal Kukreti, Princess Margaret Cancer Centre; Rena Buckstein and Kevin R. Imrie, Odette Cancer Centre and Sunnybrook Health Sciences Centre, Toronto; C. Tom Kouroukis, Jonathan Sussman, and Ralph M. Meyer, Margaret and Charles Juravinski Cancer Centre, Hamilton; Kang Howson-Jan, London Health Sciences Centre, London; Tara Baetz, Cancer Centre of Southeastern Ontario at Kingston General Hospital; Annette E. Hay, Marina S. Djurfeldt, Ralph M. Meyer, Bingshu E. Chen, and Lois E. Shepherd, NCIC Clinical Trials Group, Kingston; Leonard Kaizer, Credit Valley Hospital, Mississauga, Ontario; Stephen Couban and David A. MacDonald, Queen Elizabeth II Health Sciences Centre and Dalhousie University, Halifax, Nova Scotia; Morel Rubinger, Cancercare Manitoba, Winnipeg, Manitoba; Michael Voralia, Saskatoon Cancer Centre, Saskatoon, Saskatchewan; Harold J. Olney, Centre Hospitalier de l'Université de Montréal-Hopital Notre Dame, Montreal, Quebec; A. Robert Turner, Cross Cancer Institute, Edmonton, Alberta, Canada; Massimo Federico, University of Modena and Reggio Emilia, Modena; Nicola Di Renzo, Ospedale Vito Fazzi, Leece, Italy., MacDonald DA; Michael Crump, John Kuruvilla, and Vishal Kukreti, Princess Margaret Cancer Centre; Rena Buckstein and Kevin R. Imrie, Odette Cancer Centre and Sunnybrook Health Sciences Centre, Toronto; C. Tom Kouroukis, Jonathan Sussman, and Ralph M. Meyer, Margaret and Charles Juravinski Cancer Centre, Hamilton; Kang Howson-Jan, London Health Sciences Centre, London; Tara Baetz, Cancer Centre of Southeastern Ontario at Kingston General Hospital; Annette E. Hay, Marina S. Djurfeldt, Ralph M. Meyer, Bingshu E. Chen, and Lois E. Shepherd, NCIC Clinical Trials Group, Kingston; Leonard Kaizer, Credit Valley Hospital, Mississauga, Ontario; Stephen Couban and David A. MacDonald, Queen Elizabeth II Health Sciences Centre and Dalhousie University, Halifax, Nova Scotia; Morel Rubinger, Cancercare Manitoba, Winnipeg, Manitoba; Michael Voralia, Saskatoon Cancer Centre, Saskatoon, Saskatchewan; Harold J. Olney, Centre Hospitalier de l'Université de Montréal-Hopital Notre Dame, Montreal, Quebec; A. Robert Turner, Cross Cancer Institute, Edmonton, Alberta, Canada; Massimo Federico, University of Modena and Reggio Emilia, Modena; Nicola Di Renzo, Ospedale Vito Fazzi, Leece, Italy., Kukreti V; Michael Crump, John Kuruvilla, and Vishal Kukreti, Princess Margaret Cancer Centre; Rena Buckstein and Kevin R. Imrie, Odette Cancer Centre and Sunnybrook Health Sciences Centre, Toronto; C. Tom Kouroukis, Jonathan Sussman, and Ralph M. Meyer, Margaret and Charles Juravinski Cancer Centre, Hamilton; Kang Howson-Jan, London Health Sciences Centre, London; Tara Baetz, Cancer Centre of Southeastern Ontario at Kingston General Hospital; Annette E. Hay, Marina S. Djurfeldt, Ralph M. Meyer, Bingshu E. Chen, and Lois E. Shepherd, NCIC Clinical Trials Group, Kingston; Leonard Kaizer, Credit Valley Hospital, Mississauga, Ontario; Stephen Couban and David A. MacDonald, Queen Elizabeth II Health Sciences Centre and Dalhousie University, Halifax, Nova Scotia; Morel Rubinger, Cancercare Manitoba, Winnipeg, Manitoba; Michael Voralia, Saskatoon Cancer Centre, Saskatoon, Saskatchewan; Harold J. Olney, Centre Hospitalier de l'Université de Montréal-Hopital Notre Dame, Montreal, Quebec; A. Robert Turner, Cross Cancer Institute, Edmonton, Alberta, Canada; Massimo Federico, University of Modena and Reggio Emilia, Modena; Nicola Di Renzo, Ospedale Vito Fazzi, Leece, Italy., Kouroukis CT; Michael Crump, John Kuruvilla, and Vishal Kukreti, Princess Margaret Cancer Centre; Rena Buckstein and Kevin R. Imrie, Odette Cancer Centre and Sunnybrook Health Sciences Centre, Toronto; C. Tom Kouroukis, Jonathan Sussman, and Ralph M. Meyer, Margaret and Charles Juravinski Cancer Centre, Hamilton; Kang Howson-Jan, London Health Sciences Centre, London; Tara Baetz, Cancer Centre of Southeastern Ontario at Kingston General Hospital; Annette E. Hay, Marina S. Djurfeldt, Ralph M. Meyer, Bingshu E. Chen, and Lois E. Shepherd, NCIC Clinical Trials Group, Kingston; Leonard Kaizer, Credit Valley Hospital, Mississauga, Ontario; Stephen Couban and David A. MacDonald, Queen Elizabeth II Health Sciences Centre and Dalhousie University, Halifax, Nova Scotia; Morel Rubinger, Cancercare Manitoba, Winnipeg, Manitoba; Michael Voralia, Saskatoon Cancer Centre, Saskatoon, Saskatchewan; Harold J. Olney, Centre Hospitalier de l'Université de Montréal-Hopital Notre Dame, Montreal, Quebec; A. Robert Turner, Cross Cancer Institute, Edmonton, Alberta, Canada; Massimo Federico, University of Modena and Reggio Emilia, Modena; Nicola Di Renzo, Ospedale Vito Fazzi, Leece, Italy., Rubinger M; Michael Crump, John Kuruvilla, and Vishal Kukreti, Princess Margaret Cancer Centre; Rena Buckstein and Kevin R. Imrie, Odette Cancer Centre and Sunnybrook Health Sciences Centre, Toronto; C. Tom Kouroukis, Jonathan Sussman, and Ralph M. Meyer, Margaret and Charles Juravinski Cancer Centre, Hamilton; Kang Howson-Jan, London Health Sciences Centre, London; Tara Baetz, Cancer Centre of Southeastern Ontario at Kingston General Hospital; Annette E. Hay, Marina S. Djurfeldt, Ralph M. Meyer, Bingshu E. Chen, and Lois E. Shepherd, NCIC Clinical Trials Group, Kingston; Leonard Kaizer, Credit Valley Hospital, Mississauga, Ontario; Stephen Couban and David A. MacDonald, Queen Elizabeth II Health Sciences Centre and Dalhousie University, Halifax, Nova Scotia; Morel Rubinger, Cancercare Manitoba, Winnipeg, Manitoba; Michael Voralia, Saskatoon Cancer Centre, Saskatoon, Saskatchewan; Harold J. Olney, Centre Hospitalier de l'Université de Montréal-Hopital Notre Dame, Montreal, Quebec; A. Robert Turner, Cross Cancer Institute, Edmonton, Alberta, Canada; Massimo Federico, University of Modena and Reggio Emilia, Modena; Nicola Di Renzo, Ospedale Vito Fazzi, Leece, Italy., Buckstein R; Michael Crump, John Kuruvilla, and Vishal Kukreti, Princess Margaret Cancer Centre; Rena Buckstein and Kevin R. Imrie, Odette Cancer Centre and Sunnybrook Health Sciences Centre, Toronto; C. Tom Kouroukis, Jonathan Sussman, and Ralph M. Meyer, Margaret and Charles Juravinski Cancer Centre, Hamilton; Kang Howson-Jan, London Health Sciences Centre, London; Tara Baetz, Cancer Centre of Southeastern Ontario at Kingston General Hospital; Annette E. Hay, Marina S. Djurfeldt, Ralph M. Meyer, Bingshu E. Chen, and Lois E. Shepherd, NCIC Clinical Trials Group, Kingston; Leonard Kaizer, Credit Valley Hospital, Mississauga, Ontario; Stephen Couban and David A. MacDonald, Queen Elizabeth II Health Sciences Centre and Dalhousie University, Halifax, Nova Scotia; Morel Rubinger, Cancercare Manitoba, Winnipeg, Manitoba; Michael Voralia, Saskatoon Cancer Centre, Saskatoon, Saskatchewan; Harold J. Olney, Centre Hospitalier de l'Université de Montréal-Hopital Notre Dame, Montreal, Quebec; A. Robert Turner, Cross Cancer Institute, Edmonton, Alberta, Canada; Massimo Federico, University of Modena and Reggio Emilia, Modena; Nicola Di Renzo, Ospedale Vito Fazzi, Leece, Italy., Imrie KR; Michael Crump, John Kuruvilla, and Vishal Kukreti, Princess Margaret Cancer Centre; Rena Buckstein and Kevin R. Imrie, Odette Cancer Centre and Sunnybrook Health Sciences Centre, Toronto; C. Tom Kouroukis, Jonathan Sussman, and Ralph M. Meyer, Margaret and Charles Juravinski Cancer Centre, Hamilton; Kang Howson-Jan, London Health Sciences Centre, London; Tara Baetz, Cancer Centre of Southeastern Ontario at Kingston General Hospital; Annette E. Hay, Marina S. Djurfeldt, Ralph M. Meyer, Bingshu E. Chen, and Lois E. Shepherd, NCIC Clinical Trials Group, Kingston; Leonard Kaizer, Credit Valley Hospital, Mississauga, Ontario; Stephen Couban and David A. MacDonald, Queen Elizabeth II Health Sciences Centre and Dalhousie University, Halifax, Nova Scotia; Morel Rubinger, Cancercare Manitoba, Winnipeg, Manitoba; Michael Voralia, Saskatoon Cancer Centre, Saskatoon, Saskatchewan; Harold J. Olney, Centre Hospitalier de l'Université de Montréal-Hopital Notre Dame, Montreal, Quebec; A. Robert Turner, Cross Cancer Institute, Edmonton, Alberta, Canada; Massimo Federico, University of Modena and Reggio Emilia, Modena; Nicola Di Renzo, Ospedale Vito Fazzi, Leece, Italy., Federico M; Michael Crump, John Kuruvilla, and Vishal Kukreti, Princess Margaret Cancer Centre; Rena Buckstein and Kevin R. Imrie, Odette Cancer Centre and Sunnybrook Health Sciences Centre, Toronto; C. Tom Kouroukis, Jonathan Sussman, and Ralph M. Meyer, Margaret and Charles Juravinski Cancer Centre, Hamilton; Kang Howson-Jan, London Health Sciences Centre, London; Tara Baetz, Cancer Centre of Southeastern Ontario at Kingston General Hospital; Annette E. Hay, Marina S. Djurfeldt, Ralph M. Meyer, Bingshu E. Chen, and Lois E. Shepherd, NCIC Clinical Trials Group, Kingston; Leonard Kaizer, Credit Valley Hospital, Mississauga, Ontario; Stephen Couban and David A. MacDonald, Queen Elizabeth II Health Sciences Centre and Dalhousie University, Halifax, Nova Scotia; Morel Rubinger, Cancercare Manitoba, Winnipeg, Manitoba; Michael Voralia, Saskatoon Cancer Centre, Saskatoon, Saskatchewan; Harold J. Olney, Centre Hospitalier de l'Université de Montréal-Hopital Notre Dame, Montreal, Quebec; A. Robert Turner, Cross Cancer Institute, Edmonton, Alberta, Canada; Massimo Federico, University of Modena and Reggio Emilia, Modena; Nicola Di Renzo, Ospedale Vito Fazzi, Leece, Italy., Di Renzo N; Michael Crump, John Kuruvilla, and Vishal Kukreti, Princess Margaret Cancer Centre; Rena Buckstein and Kevin R. Imrie, Odette Cancer Centre and Sunnybrook Health Sciences Centre, Toronto; C. Tom Kouroukis, Jonathan Sussman, and Ralph M. Meyer, Margaret and Charles Juravinski Cancer Centre, Hamilton; Kang Howson-Jan, London Health Sciences Centre, London; Tara Baetz, Cancer Centre of Southeastern Ontario at Kingston General Hospital; Annette E. Hay, Marina S. Djurfeldt, Ralph M. Meyer, Bingshu E. Chen, and Lois E. Shepherd, NCIC Clinical Trials Group, Kingston; Leonard Kaizer, Credit Valley Hospital, Mississauga, Ontario; Stephen Couban and David A. MacDonald, Queen Elizabeth II Health Sciences Centre and Dalhousie University, Halifax, Nova Scotia; Morel Rubinger, Cancercare Manitoba, Winnipeg, Manitoba; Michael Voralia, Saskatoon Cancer Centre, Saskatoon, Saskatchewan; Harold J. Olney, Centre Hospitalier de l'Université de Montréal-Hopital Notre Dame, Montreal, Quebec; A. Robert Turner, Cross Cancer Institute, Edmonton, Alberta, Canada; Massimo Federico, University of Modena and Reggio Emilia, Modena; Nicola Di Renzo, Ospedale Vito Fazzi, Leece, Italy., Howson-Jan K; Michael Crump, John Kuruvilla, and Vishal Kukreti, Princess Margaret Cancer Centre; Rena Buckstein and Kevin R. Imrie, Odette Cancer Centre and Sunnybrook Health Sciences Centre, Toronto; C. Tom Kouroukis, Jonathan Sussman, and Ralph M. Meyer, Margaret and Charles Juravinski Cancer Centre, Hamilton; Kang Howson-Jan, London Health Sciences Centre, London; Tara Baetz, Cancer Centre of Southeastern Ontario at Kingston General Hospital; Annette E. Hay, Marina S. Djurfeldt, Ralph M. Meyer, Bingshu E. Chen, and Lois E. Shepherd, NCIC Clinical Trials Group, Kingston; Leonard Kaizer, Credit Valley Hospital, Mississauga, Ontario; Stephen Couban and David A. MacDonald, Queen Elizabeth II Health Sciences Centre and Dalhousie University, Halifax, Nova Scotia; Morel Rubinger, Cancercare Manitoba, Winnipeg, Manitoba; Michael Voralia, Saskatoon Cancer Centre, Saskatoon, Saskatchewan; Harold J. Olney, Centre Hospitalier de l'Université de Montréal-Hopital Notre Dame, Montreal, Quebec; A. Robert Turner, Cross Cancer Institute, Edmonton, Alberta, Canada; Massimo Federico, University of Modena and Reggio Emilia, Modena; Nicola Di Renzo, Ospedale Vito Fazzi, Leece, Italy., Baetz T; Michael Crump, John Kuruvilla, and Vishal Kukreti, Princess Margaret Cancer Centre; Rena Buckstein and Kevin R. Imrie, Odette Cancer Centre and Sunnybrook Health Sciences Centre, Toronto; C. Tom Kouroukis, Jonathan Sussman, and Ralph M. Meyer, Margaret and Charles Juravinski Cancer Centre, Hamilton; Kang Howson-Jan, London Health Sciences Centre, London; Tara Baetz, Cancer Centre of Southeastern Ontario at Kingston General Hospital; Annette E. Hay, Marina S. Djurfeldt, Ralph M. Meyer, Bingshu E. Chen, and Lois E. Shepherd, NCIC Clinical Trials Group, Kingston; Leonard Kaizer, Credit Valley Hospital, Mississauga, Ontario; Stephen Couban and David A. MacDonald, Queen Elizabeth II Health Sciences Centre and Dalhousie University, Halifax, Nova Scotia; Morel Rubinger, Cancercare Manitoba, Winnipeg, Manitoba; Michael Voralia, Saskatoon Cancer Centre, Saskatoon, Saskatchewan; Harold J. Olney, Centre Hospitalier de l'Université de Montréal-Hopital Notre Dame, Montreal, Quebec; A. Robert Turner, Cross Cancer Institute, Edmonton, Alberta, Canada; Massimo Federico, University of Modena and Reggio Emilia, Modena; Nicola Di Renzo, Ospedale Vito Fazzi, Leece, Italy., Kaizer L; Michael Crump, John Kuruvilla, and Vishal Kukreti, Princess Margaret Cancer Centre; Rena Buckstein and Kevin R. Imrie, Odette Cancer Centre and Sunnybrook Health Sciences Centre, Toronto; C. Tom Kouroukis, Jonathan Sussman, and Ralph M. Meyer, Margaret and Charles Juravinski Cancer Centre, Hamilton; Kang Howson-Jan, London Health Sciences Centre, London; Tara Baetz, Cancer Centre of Southeastern Ontario at Kingston General Hospital; Annette E. Hay, Marina S. Djurfeldt, Ralph M. Meyer, Bingshu E. Chen, and Lois E. Shepherd, NCIC Clinical Trials Group, Kingston; Leonard Kaizer, Credit Valley Hospital, Mississauga, Ontario; Stephen Couban and David A. MacDonald, Queen Elizabeth II Health Sciences Centre and Dalhousie University, Halifax, Nova Scotia; Morel Rubinger, Cancercare Manitoba, Winnipeg, Manitoba; Michael Voralia, Saskatoon Cancer Centre, Saskatoon, Saskatchewan; Harold J. Olney, Centre Hospitalier de l'Université de Montréal-Hopital Notre Dame, Montreal, Quebec; A. Robert Turner, Cross Cancer Institute, Edmonton, Alberta, Canada; Massimo Federico, University of Modena and Reggio Emilia, Modena; Nicola Di Renzo, Ospedale Vito Fazzi, Leece, Italy., Voralia M; Michael Crump, John Kuruvilla, and Vishal Kukreti, Princess Margaret Cancer Centre; Rena Buckstein and Kevin R. Imrie, Odette Cancer Centre and Sunnybrook Health Sciences Centre, Toronto; C. Tom Kouroukis, Jonathan Sussman, and Ralph M. Meyer, Margaret and Charles Juravinski Cancer Centre, Hamilton; Kang Howson-Jan, London Health Sciences Centre, London; Tara Baetz, Cancer Centre of Southeastern Ontario at Kingston General Hospital; Annette E. Hay, Marina S. Djurfeldt, Ralph M. Meyer, Bingshu E. Chen, and Lois E. Shepherd, NCIC Clinical Trials Group, Kingston; Leonard Kaizer, Credit Valley Hospital, Mississauga, Ontario; Stephen Couban and David A. MacDonald, Queen Elizabeth II Health Sciences Centre and Dalhousie University, Halifax, Nova Scotia; Morel Rubinger, Cancercare Manitoba, Winnipeg, Manitoba; Michael Voralia, Saskatoon Cancer Centre, Saskatoon, Saskatchewan; Harold J. Olney, Centre Hospitalier de l'Université de Montréal-Hopital Notre Dame, Montreal, Quebec; A. Robert Turner, Cross Cancer Institute, Edmonton, Alberta, Canada; Massimo Federico, University of Modena and Reggio Emilia, Modena; Nicola Di Renzo, Ospedale Vito Fazzi, Leece, Italy., Olney HJ; Michael Crump, John Kuruvilla, and Vishal Kukreti, Princess Margaret Cancer Centre; Rena Buckstein and Kevin R. Imrie, Odette Cancer Centre and Sunnybrook Health Sciences Centre, Toronto; C. Tom Kouroukis, Jonathan Sussman, and Ralph M. Meyer, Margaret and Charles Juravinski Cancer Centre, Hamilton; Kang Howson-Jan, London Health Sciences Centre, London; Tara Baetz, Cancer Centre of Southeastern Ontario at Kingston General Hospital; Annette E. Hay, Marina S. Djurfeldt, Ralph M. Meyer, Bingshu E. Chen, and Lois E. Shepherd, NCIC Clinical Trials Group, Kingston; Leonard Kaizer, Credit Valley Hospital, Mississauga, Ontario; Stephen Couban and David A. MacDonald, Queen Elizabeth II Health Sciences Centre and Dalhousie University, Halifax, Nova Scotia; Morel Rubinger, Cancercare Manitoba, Winnipeg, Manitoba; Michael Voralia, Saskatoon Cancer Centre, Saskatoon, Saskatchewan; Harold J. Olney, Centre Hospitalier de l'Université de Montréal-Hopital Notre Dame, Montreal, Quebec; A. Robert Turner, Cross Cancer Institute, Edmonton, Alberta, Canada; Massimo Federico, University of Modena and Reggio Emilia, Modena; Nicola Di Renzo, Ospedale Vito Fazzi, Leece, Italy., Turner AR; Michael Crump, John Kuruvilla, and Vishal Kukreti, Princess Margaret Cancer Centre; Rena Buckstein and Kevin R. Imrie, Odette Cancer Centre and Sunnybrook Health Sciences Centre, Toronto; C. Tom Kouroukis, Jonathan Sussman, and Ralph M. Meyer, Margaret and Charles Juravinski Cancer Centre, Hamilton; Kang Howson-Jan, London Health Sciences Centre, London; Tara Baetz, Cancer Centre of Southeastern Ontario at Kingston General Hospital; Annette E. Hay, Marina S. Djurfeldt, Ralph M. Meyer, Bingshu E. Chen, and Lois E. Shepherd, NCIC Clinical Trials Group, Kingston; Leonard Kaizer, Credit Valley Hospital, Mississauga, Ontario; Stephen Couban and David A. MacDonald, Queen Elizabeth II Health Sciences Centre and Dalhousie University, Halifax, Nova Scotia; Morel Rubinger, Cancercare Manitoba, Winnipeg, Manitoba; Michael Voralia, Saskatoon Cancer Centre, Saskatoon, Saskatchewan; Harold J. Olney, Centre Hospitalier de l'Université de Montréal-Hopital Notre Dame, Montreal, Quebec; A. Robert Turner, Cross Cancer Institute, Edmonton, Alberta, Canada; Massimo Federico, University of Modena and Reggio Emilia, Modena; Nicola Di Renzo, Ospedale Vito Fazzi, Leece, Italy., Sussman J; Michael Crump, John Kuruvilla, and Vishal Kukreti, Princess Margaret Cancer Centre; Rena Buckstein and Kevin R. Imrie, Odette Cancer Centre and Sunnybrook Health Sciences Centre, Toronto; C. Tom Kouroukis, Jonathan Sussman, and Ralph M. Meyer, Margaret and Charles Juravinski Cancer Centre, Hamilton; Kang Howson-Jan, London Health Sciences Centre, London; Tara Baetz, Cancer Centre of Southeastern Ontario at Kingston General Hospital; Annette E. Hay, Marina S. Djurfeldt, Ralph M. Meyer, Bingshu E. Chen, and Lois E. Shepherd, NCIC Clinical Trials Group, Kingston; Leonard Kaizer, Credit Valley Hospital, Mississauga, Ontario; Stephen Couban and David A. MacDonald, Queen Elizabeth II Health Sciences Centre and Dalhousie University, Halifax, Nova Scotia; Morel Rubinger, Cancercare Manitoba, Winnipeg, Manitoba; Michael Voralia, Saskatoon Cancer Centre, Saskatoon, Saskatchewan; Harold J. Olney, Centre Hospitalier de l'Université de Montréal-Hopital Notre Dame, Montreal, Quebec; A. Robert Turner, Cross Cancer Institute, Edmonton, Alberta, Canada; Massimo Federico, University of Modena and Reggio Emilia, Modena; Nicola Di Renzo, Ospedale Vito Fazzi, Leece, Italy., Hay AE; Michael Crump, John Kuruvilla, and Vishal Kukreti, Princess Margaret Cancer Centre; Rena Buckstein and Kevin R. Imrie, Odette Cancer Centre and Sunnybrook Health Sciences Centre, Toronto; C. Tom Kouroukis, Jonathan Sussman, and Ralph M. Meyer, Margaret and Charles Juravinski Cancer Centre, Hamilton; Kang Howson-Jan, London Health Sciences Centre, London; Tara Baetz, Cancer Centre of Southeastern Ontario at Kingston General Hospital; Annette E. Hay, Marina S. Djurfeldt, Ralph M. Meyer, Bingshu E. Chen, and Lois E. Shepherd, NCIC Clinical Trials Group, Kingston; Leonard Kaizer, Credit Valley Hospital, Mississauga, Ontario; Stephen Couban and David A. MacDonald, Queen Elizabeth II Health Sciences Centre and Dalhousie University, Halifax, Nova Scotia; Morel Rubinger, Cancercare Manitoba, Winnipeg, Manitoba; Michael Voralia, Saskatoon Cancer Centre, Saskatoon, Saskatchewan; Harold J. Olney, Centre Hospitalier de l'Université de Montréal-Hopital Notre Dame, Montreal, Quebec; A. Robert Turner, Cross Cancer Institute, Edmonton, Alberta, Canada; Massimo Federico, University of Modena and Reggio Emilia, Modena; Nicola Di Renzo, Ospedale Vito Fazzi, Leece, Italy., Djurfeldt MS; Michael Crump, John Kuruvilla, and Vishal Kukreti, Princess Margaret Cancer Centre; Rena Buckstein and Kevin R. Imrie, Odette Cancer Centre and Sunnybrook Health Sciences Centre, Toronto; C. Tom Kouroukis, Jonathan Sussman, and Ralph M. Meyer, Margaret and Charles Juravinski Cancer Centre, Hamilton; Kang Howson-Jan, London Health Sciences Centre, London; Tara Baetz, Cancer Centre of Southeastern Ontario at Kingston General Hospital; Annette E. Hay, Marina S. Djurfeldt, Ralph M. Meyer, Bingshu E. Chen, and Lois E. Shepherd, NCIC Clinical Trials Group, Kingston; Leonard Kaizer, Credit Valley Hospital, Mississauga, Ontario; Stephen Couban and David A. MacDonald, Queen Elizabeth II Health Sciences Centre and Dalhousie University, Halifax, Nova Scotia; Morel Rubinger, Cancercare Manitoba, Winnipeg, Manitoba; Michael Voralia, Saskatoon Cancer Centre, Saskatoon, Saskatchewan; Harold J. Olney, Centre Hospitalier de l'Université de Montréal-Hopital Notre Dame, Montreal, Quebec; A. Robert Turner, Cross Cancer Institute, Edmonton, Alberta, Canada; Massimo Federico, University of Modena and Reggio Emilia, Modena; Nicola Di Renzo, Ospedale Vito Fazzi, Leece, Italy., Meyer RM; Michael Crump, John Kuruvilla, and Vishal Kukreti, Princess Margaret Cancer Centre; Rena Buckstein and Kevin R. Imrie, Odette Cancer Centre and Sunnybrook Health Sciences Centre, Toronto; C. Tom Kouroukis, Jonathan Sussman, and Ralph M. Meyer, Margaret and Charles Juravinski Cancer Centre, Hamilton; Kang Howson-Jan, London Health Sciences Centre, London; Tara Baetz, Cancer Centre of Southeastern Ontario at Kingston General Hospital; Annette E. Hay, Marina S. Djurfeldt, Ralph M. Meyer, Bingshu E. Chen, and Lois E. Shepherd, NCIC Clinical Trials Group, Kingston; Leonard Kaizer, Credit Valley Hospital, Mississauga, Ontario; Stephen Couban and David A. MacDonald, Queen Elizabeth II Health Sciences Centre and Dalhousie University, Halifax, Nova Scotia; Morel Rubinger, Cancercare Manitoba, Winnipeg, Manitoba; Michael Voralia, Saskatoon Cancer Centre, Saskatoon, Saskatchewan; Harold J. Olney, Centre Hospitalier de l'Université de Montréal-Hopital Notre Dame, Montreal, Quebec; A. Robert Turner, Cross Cancer Institute, Edmonton, Alberta, Canada; Massimo Federico, University of Modena and Reggio Emilia, Modena; Nicola Di Renzo, Ospedale Vito Fazzi, Leece, Italy., Chen BE; Michael Crump, John Kuruvilla, and Vishal Kukreti, Princess Margaret Cancer Centre; Rena Buckstein and Kevin R. Imrie, Odette Cancer Centre and Sunnybrook Health Sciences Centre, Toronto; C. Tom Kouroukis, Jonathan Sussman, and Ralph M. Meyer, Margaret and Charles Juravinski Cancer Centre, Hamilton; Kang Howson-Jan, London Health Sciences Centre, London; Tara Baetz, Cancer Centre of Southeastern Ontario at Kingston General Hospital; Annette E. Hay, Marina S. Djurfeldt, Ralph M. Meyer, Bingshu E. Chen, and Lois E. Shepherd, NCIC Clinical Trials Group, Kingston; Leonard Kaizer, Credit Valley Hospital, Mississauga, Ontario; Stephen Couban and David A. MacDonald, Queen Elizabeth II Health Sciences Centre and Dalhousie University, Halifax, Nova Scotia; Morel Rubinger, Cancercare Manitoba, Winnipeg, Manitoba; Michael Voralia, Saskatoon Cancer Centre, Saskatoon, Saskatchewan; Harold J. Olney, Centre Hospitalier de l'Université de Montréal-Hopital Notre Dame, Montreal, Quebec; A. Robert Turner, Cross Cancer Institute, Edmonton, Alberta, Canada; Massimo Federico, University of Modena and Reggio Emilia, Modena; Nicola Di Renzo, Ospedale Vito Fazzi, Leece, Italy., Shepherd LE; Michael Crump, John Kuruvilla, and Vishal Kukreti, Princess Margaret Cancer Centre; Rena Buckstein and Kevin R. Imrie, Odette Cancer Centre and Sunnybrook Health Sciences Centre, Toronto; C. Tom Kouroukis, Jonathan Sussman, and Ralph M. Meyer, Margaret and Charles Juravinski Cancer Centre, Hamilton; Kang Howson-Jan, London Health Sciences Centre, London; Tara Baetz, Cancer Centre of Southeastern Ontario at Kingston General Hospital; Annette E. Hay, Marina S. Djurfeldt, Ralph M. Meyer, Bingshu E. Chen, and Lois E. Shepherd, NCIC Clinical Trials Group, Kingston; Leonard Kaizer, Credit Valley Hospital, Mississauga, Ontario; Stephen Couban and David A. MacDonald, Queen Elizabeth II Health Sciences Centre and Dalhousie University, Halifax, Nova Scotia; Morel Rubinger, Cancercare Manitoba, Winnipeg, Manitoba; Michael Voralia, Saskatoon Cancer Centre, Saskatoon, Saskatchewan; Harold J. Olney, Centre Hospitalier de l'Université de Montréal-Hopital Notre Dame, Montreal, Quebec; A. Robert Turner, Cross Cancer Institute, Edmonton, Alberta, Canada; Massimo Federico, University of Modena and Reggio Emilia, Modena; Nicola Di Renzo, Ospedale Vito Fazzi, Leece, Italy.

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2014 Nov 01; Vol. 32 (31), pp. 3490-6. Date of Electronic Publication: 2014 Sep 29.

Patterns of disease progression and outcomes in a randomized trial testing ABVD alone for patients with limited-stage Hodgkin lymphoma.

Autor: Macdonald DA; National Cancer Institute of Canada Clinical Trials Group, Queens University, Kingston, Ontario, Canada., Ding K, Gospodarowicz MK, Wells WA, Pearcey RG, Connors JM, Winter JN, Horning SJ, Djurfeldt MS, Shepherd LE, Meyer RM

Publikováno v: Annals of oncology : official journal of the European Society for Medical Oncology [Ann Oncol] 2007 Oct; Vol. 18 (10), pp. 1680-4. Date of Electronic Publication: 2007 Sep 10.